MedTrace Logo

Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia

NCT02540655 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2022-10-27

No results posted yet for this study

Summary

The purpose of the clinical trial is to study the therapeutic efficacy and safety of Stemchymal® infusions for polyglutamine spinocerebellar ataxia treatment by a randomized, double-blind, placebo-controlled study design. Eligible subjects will receive Stemchymal® through intravenous infusion.

Conditions

  • Cerebellar Ataxia

Interventions

BIOLOGICAL

Stemchymal®

Patients will receive Stemchymal® through intravenous infusion

PROCEDURE

Excipients

Patients will receive excipients through intravenous infusion

Sponsors & Collaborators

  • Steminent Biotherapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2021-02-26
Completion
2021-02-26

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02540655 on ClinicalTrials.gov